Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Core Insights - The company has provided guidance for IBSRELA revenue between $250 million and $260 million for the current year, indicating strong performance expectations [1] - The company aims for peak revenue of $1 billion, demonstrating confidence in growth potential [1] - Year-over-year growth rates are highlighted as a clear indicator of the company's progress [1] Company Overview - The idea for tenapanor was first presented to the Board on December 23, 2008, marking the beginning of the company's journey [1] - The evolution of the company has been significant, leading to current revenue projections that exceed initial expectations [1] Product Performance - The journey of XPHOZAH is noted as remarkable, although specific details on its performance are not provided in the excerpt [2]